Investigational Drug Information for SEP-363856
✉ Email this page to a colleague
What is the drug development status for SEP-363856?
SEP-363856 is an investigational drug.
There have been 26 clinical trials for SEP-363856.
The most recent clinical trial was a Phase 2 trial, which was initiated on October 4th 2019.
The most common disease conditions in clinical trials are Schizophrenia, Disease, and Mental Disorders. The leading clinical trial sponsors are Sunovion, Sumitomo Dainippon Pharma Co., Ltd., and Sumitomo Pharma Co., Ltd.
There is one US patent protecting this investigational drug and sixty-six international patents.
Summary for SEP-363856
| US Patents | 1 |
| International Patents | 66 |
| US Patent Applications | 33 |
| WIPO Patent Applications | 6 |
| Japanese Patent Applications | 3 |
| Clinical Trial Progress | Phase 2 (2019-10-04) |
| Vendors | 18 |
Recent Clinical Trials for SEP-363856
| Title | Sponsor | Phase |
|---|---|---|
| A Clinical Study to Learn if SEP-363856 Has Physical Dependence in Adults With Schizophrenia | Sunovion | Phase 1 |
| An Extension Study to a Clinical Study That Will Continue to Evalute the Effectiveness and Safety of SEP-363856 in People With Schizophrenia That Switch to SEP-363856 From Their From Their Current Antisychotic Medication | Sunovion | Phase 3 |
| A Clinical Study That Will Meaure How Well SEP-363856 Works and How Safe it is in Adults With Generalized Anixety Disorder | Sunovion | Phase 2/Phase 3 |
Clinical Trial Summary for SEP-363856
Top disease conditions for SEP-363856
Top clinical trial sponsors for SEP-363856
US Patents for SEP-363856
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| SEP-363856 | ⤷ Subscribe | Multicyclic compounds and methods of use thereof | Sunovion Pharmaceuticals Inc. (Marlborough, MA) PGI Drug Discovery LLC. (Tarrytown, NY) | ⤷ Subscribe |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for SEP-363856
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| SEP-363856 | Australia | AU2010325925 | 2029-12-04 | ⤷ Subscribe |
| SEP-363856 | Australia | AU2016200448 | 2029-12-04 | ⤷ Subscribe |
| SEP-363856 | Australia | AU2017248551 | 2029-12-04 | ⤷ Subscribe |
| SEP-363856 | Brazil | BR112012013431 | 2029-12-04 | ⤷ Subscribe |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
